Pyott David E I exercised Options tied to Tarsus Pharmaceuticals on 2026-09-15, leaving him with 9,575 shares and representing about 2.1% of his resulting share holding. The exercise also represented about 24.9% of his prior derivative securities holding, giving investors two stated measures of the position change.
Key Highlights
- Pyott David E I’s option exercise left him with 9,575 Tarsus Pharmaceuticals shares.
- The exercise represented about 24.9% of his prior derivative securities holding.
- The Tarsus Pharmaceuticals transaction represented about 2.1% of Pyott David E I’s resulting share holding.
Pyott David E I exercised options tied to Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) on 15 September 2026, leaving him with 9,575 shares. The transaction represented about 2.1% of his resulting share holding.
Tarsus Option Exercise Recorded on 15 September 2026
Pyott David E I is identified as a director of Tarsus Pharmaceuticals. The transaction involved options for Tarsus Pharmaceuticals shares and derivative securities. The post-transaction share position stood at 9,575. The reported transaction percentage for that holding was about 2.1%.
Derivative Position Measured Against Prior Holding
The transaction also represented about 24.9% of Pyott David E I’s prior derivative securities holding in Tarsus Pharmaceuticals. That percentage applies to the derivative securities position rather than the resulting share holding. Tarsus Pharmaceuticals is the named issuer associated with both positions.
FAQs
Q: How many Tarsus Pharmaceuticals shares did Pyott David E I own after the option exercise?
A: Pyott David E I held 9,575 Tarsus Pharmaceuticals shares after the transaction. The position followed an option exercise recorded on 15 September 2026.
Q: What percentage of Pyott David E I’s resulting share holding did the transaction represent?
A: The Tarsus Pharmaceuticals transaction represented about 2.1% of Pyott David E I’s resulting share holding. That percentage relates to the shares position.
Q: What did transaction code M mean in the Tarsus Pharmaceuticals transaction?
A: Transaction code M classified the activity as an option exercise. The transaction also represented about 24.9% of Pyott David E I’s prior derivative securities holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.